Erick Figueiredo Saldanha, MD
Erick Figueiredo Saldanha, MD
Specialty: Medical Oncology
Program: Cutaneous Oncology
Language(s): English, Portuguese
-
Overview
Cancer Focus:
Basal Cell Carcinoma, Melanoma, Skin Cancer (Nonmelanoma)Dr. Saldanha is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and Research Institute and an assistant professor in the department of oncologic sciences at the University of South Florida Morsani College of Medicine. Dr. Saldanha specializes in early drug development, with a focus on phase I clinical trials for melanoma and cutaneous malignancies. He has a particular interest in uveal melanoma and rare skin cancers.
His clinical research focuses on proof-of-concept and proof-of-mechanism studies, as well as biomarker-driven early-phase clinical trials, with an emphasis on cutaneous and rare malignancies. His translational research centers on the clinical application of circulating nucleic acid biomarkers and the integration of large-scale omics data to advance personalized cancer care.
Before joining Moffitt Cancer Center, Dr. Figueiredo Saldanha completed an advanced clinical research fellowship in melanoma, skin malignancies and adoptive cellular therapy for solid tumors. He then completed a fellowship in the Bras Drug Development and Phase I/Experimental Therapeutics Program within the Division of Medical Oncology and Hematology at the University of Toronto and Princess Margaret Cancer Centre in Toronto, Canada.
-
Publications
- Pisapia P, Mirallas O, Saldanha EF, Borea R. Cancer in a Drop: Liquid biopsy insights from AACR 2026. J Liq Biopsy. 2026 Sep.13:100488. Pubmedid: 42769118. Pmcid: PMC13590274.
- Costa Filho VO, Noronha MM, Costa Passos PR, Holanda Lopes CD, Leite GGF, Maia DCC, de Souza Wanderley CW, Saibil SD, Saldanha EF. Genomic Landscape and Clinical Actionability of Skin Adnexal Carcinomas. JCO Precis Oncol. 2026 Oct.10(10):e2600300. Pubmedid: 42868338.
- Borea R, Saldanha EF, Maheswaran S, Nicolo E, Singhal S, Pontolillo L, de Miguel Perez D, Venetis K, Dipasquale A, Ghazali N, Pisapia P, Franco AO, Gouda MA, Reduzzi C. Cancer in a drop: Advances in liquid biopsy in 2024. Crit Rev Oncol Hematol. 2025 Sep.213:104776. Pubmedid: 40447209.
- Leite LF, Costa de Almeida LF, Diniz da Conceição L, Macambira Noronha M, Belotto M, Saldanha EF, Megid TBC, D'Alpino Peixoto R, Gyawali B. Disease-free survival as a surrogate for overall survival in early-stage pancreatic cancer trials: a correlation meta-analysis. BMJ Oncol. 2025 May.4(1):e000766. Pubmedid: 40519225. Pmcid: PMC12164301.
- Macambira Noronha M, Leite da Silva LF, Reis PCA, Evangelista Ponte Conrado J, Baccili Cury Megid T, Saldanha EF. Peritoneal Tumor DNA as a Prognostic Biomarker in Pancreatic Cancer: A Systematic Review and Meta-Analysis. Pancreas. 2025 May.54(5):e496-e499. Pubmedid: 39591536.
- Filho VOC, Mesquita FP, Saldanha EF, Passos PRC, Noronha MM, Rabenhorst SHB. Multi-cohort gene expression model enhances prognostic stratification in diffuse large B-cell lymphoma. Hematol Transfus Cell Ther. 2025 Jun.47(3):103847. Pubmedid: 40513296. Pmcid: PMC12205312.
- Valenza C, Saldanha EF, Gong Y, De Placido P, Gritsch D, Ortiz H, Trapani D, Conforti F, Cremolini C, Peters S, Mateo J, Subbiah V, Parsons HA, Partridge AH, Curigliano G. Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis. Ann Oncol. 2025 Jul.36(7):726-736. Pubmedid: 40187491.
- Passos PRC, Filho VOC, Noronha MM, Hyppolito EB, Saldanha EF, Motta RV. Influence of glucagon-like peptide-1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2025 Jan.40(1):67-77. Pubmedid: 39322970.
- Saldanha EF, Cordeiro de Lima VC, Fares A, Corassa M, Gil-Santana L, Arrieta O, Soler J, Chamorro DF, Rodrigues J, Carioca Freitas H, Rojas L, Zuluaga J, Cardona AF. Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP). Oncologist. 2025 Feb.30(2). Pubmedid: 40036771. Pmcid: PMC11879184.
- Leite da Silva LF, Saldanha EF, de Menezes JSA, Halamy Pereira L, de Bragança Dos Santos JAR, Buonopane IR, de Souza EM, de Menezes CUG, Lopes G. Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis. Oncologist. 2025 Feb.30(2). Pubmedid: 39998904. Pmcid: PMC11853598.
- Saldanha EF, Ribeiro MF, Hirsch I, Spreafico A, Saibil SD, Butler MO. How we treat patients with metastatic uveal melanoma. ESMO Open. 2025 Apr.10(4):104496. Pubmedid: 40112696. Pmcid: PMC11979469.
- Saldanha EF, Nicolo E, Venetis K, de Miguel-Perez D, Ortega-Franco A, Dipasquale A, Gouda MA, Singhal S, Adigbli G, Reduzzi C. The role of liquid biopsy as a catalyst for sustained progress in precision oncology - Perspective of the young committee of the international society of liquid biopsy. J Liq Biopsy. 2024 Sep.5:100156. Pubmedid: 40027940. Pmcid: PMC11863974.
- Saldanha EF, Powis M, Sharma D, Espin-Garcia O, Hack S, Cavalher F, Costa MR, Simoes M, Li H, Baiad A, Chen K, Mohmand Z, Nakhla P, Aguiar S, Riechelmann R, Krzyzanowska MK. Impact of the Early Phase of the COVID-19 Pandemic on the Quality of Care for Colorectal and Anal Cancers at Comprehensive Cancer Centers on Two Continents. JCO Glob Oncol. 2024 Sep.10:e2400037. Pubmedid: 39348613.
- Reduzzi C, Nicolo' E, Singhal S, Venetis K, Ortega-Franco A, de Miguel-Perez D, Dipasquale A, Gouda MA, Saldanha EF, Kasi PM, Jantus-Lewintre E, Fusco N, Malapelle U, Gandara DR, Rolfo C, Serrano MJ, Cristofanilli M. Unveiling the impact of circulating tumor cells: Two decades of discovery and clinical advancements in solid tumors. Crit Rev Oncol Hematol. 2024 Nov.203:104483. Pubmedid: 39159706.
- da Silva LFL, Saldanha EF, da Conceição LD, de Andrade Martins W, Gismondi RA, de Souza Filho EM, Peixoto RD. Efficacy and safety of trifluridine/tipiracil plus bevacizumab across different subgroups of patients with refractory colorectal cancer: a meta-analysis. Ecancermedicalscience. 2024 Jul.18:1728. Pubmedid: 39421178. Pmcid: PMC11484657.
- da Silva LFL, Saldanha EF, da Conceição LD, Noronha MM, da Silva MVMG, Peixoto RD'. Anti-EGFR Rechallenge in Metastatic Colorectal Cancer and the Role of ctDNA: A Systematic Review and Meta-analysis. J Gastrointest Cancer. 2024 Dec.56(1):28. Pubmedid: 39623250.
- Chamorro DF, Cardona AF, Rodríguez J, Ruiz-Patiño A, Arrieta O, Moreno-Pérez DA, Rojas L, Zatarain-Barrón ZL, Ardila DV, Viola L, Recondo G, Blaquier JB, Martín C, Raez L, Samtani S, Ordóñez-Reyes C, Garcia-Robledo JE, Corrales L, Sotelo C, Ricaurte L, Cuello M, Mejía S, Jaller E, Vargas C, Carranza H, Otero J, Archila P, Bermudez M, Gamez T, Russo A, Malapelle U, de Miguel Perez D, de Lima VCC, Freitas H, Saldahna E, Rolfo C, Rosell R. Genomic Landscape of Primary Resistance to Osimertinib Among Hispanic Patients with EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC): Results of an Observational Longitudinal Cohort Study. Target Oncol. 2023 May.18(3):425-440. Pubmedid: 37017806. Pmcid: PMC10192162.
- Koch Hein EC, Vilbert M, Hirsch I, Fernando Ribeiro M, Muniz TP, Fournier C, Abdulalem K, Saldanha EF, Martinez E, Spreafico A, Hogg DH, Butler MO, Saibil SD. Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre. Cancers (Basel). 2023 Aug.15(17). Pubmedid: 37686588. Pmcid: PMC10487051.
- Cordeiro de Lima VC, Corassa M, Saldanha E, Freitas H, Arrieta O, Raez L, Samtani S, Ramos M, Rojas C, Burotto M, Chamorro DF, Recondo G, Ruiz-Patiño A, Más L, Zatarain-Barrón L, Mejía S, Nicolas Minata J, Martín C, Bautista Blaquier J, Motta Guerrero R, Aliaga-Macha C, Carracedo C, Ordóñez-Reyes C, Garcia-Robledo JE, Corrales L, Sotelo C, Ricaurte L, Santoyo N, Cuello M, Jaller E, Rodríguez J, Archila P, Bermudez M, Gamez T, Russo A, Viola L, Malapelle U, de Miguel Perez D, Rolfo C, Rosell R, Cardona AF. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). Lung Cancer. 2022 Aug.170:114-121. Pubmedid: 35753125.
- de Moura Leite L, Cesca MG, Tavares MC, Santana DM, Saldanha EF, Guimarães PT, Sá DDS, Simões MFE, Viana RL, Rocha FG, Loose SK, Silva SF, Pirolli R, Fogassa CAZ, Mattos BRS, Campos FAB, Sanches SM, de Lima VCC, Pondé NF. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat. 2021 Nov.190(1):155-163. Pubmedid: 34409551.
-
Patient Comments
0 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Learn more about our patient satisfaction surveyComments
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
Learn more about our patient comments
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
Learn more about our patient satisfaction survey, ratings and comments